SCHEMBL7922668

SCHEMBL7922668

CN(CCOc1ccc(CC(N)C(=O)O)cc1)c1ccccn1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 13/20 0.62
MAPT P10636 3/20 0.62
KMT2A Q03164 2/20 0.62
PPARA Q07869 2/20 0.62
MEN1 O00255 1/20 0.62
GMNN O75496 1/20 0.62
EGFR P00533 1/20 0.62
LMNA P02545 1/20 0.62
CYP3A4 P08684 1/20 0.62
ADORA3 P0DMS8 1/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C9 P11712 1/20 0.62
ADRB3 P13945 1/20 0.62
TSHR P16473 1/20 0.62
ADRA2B P18089 1/20 0.62
NFKB1 P19838 1/20 0.62
TACR2 P21452 1/20 0.62
SLC6A2 P23975 1/20 0.62
TBXAS1 P24557 1/20 0.62
ADORA2A P29274 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9390256 0.91 PPARG (0.66) PPARGMAPTKMT2APPARAMEN1
SCHEMBL7926636 0.88 PPARG (0.54) PPARGMAPTKMT2APPARAMEN1
SCHEMBL9083895 0.87 PPARG (0.62) PPARGMAPTKMT2APPARAMEN1
SCHEMBL8063445 0.84 PPARG (0.67) PPARGMAPTKMT2APPARAMEN1
SCHEMBL9390236 0.83 PPARG (0.60) PPARGMAPTKMT2APPARAMEN1
SCHEMBL12396399 0.83 FFAR1 (0.64) PPARGMAPTKMT2APPARAMEN1
SCHEMBL3496044 0.82 PPARG (0.64) PPARGMAPTKMT2APPARAMEN1
SCHEMBL7822770 0.81 PPARG (0.55) PPARGMAPTKMT2APPARAMEN1
SCHEMBL6383227 0.81 PPARG (0.59) PPARGMAPTKMT2APPARAMEN1
SCHEMBL6385527 0.81 PPARG (0.59) PPARGMAPTKMT2APPARAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6294580-B1 FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE GLAXO WELLCOME INC. 2001-09-25 US disclosed
EP-0888317-B1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LTD (GB) 2001-09-12 EP disclosed
EP-0888317-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1999-01-07 EP disclosed
WO-1997031907-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1997-09-04 WO disclosed